This inventor holds 9 USPTO granted patents and 26 published patent applications and 2 EPO patents. Top assignees: Genmab A+s, Janssen Biotech, Inc.. Active years: 2021-2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Spring House, PA (US) (2021)
- Rydal, PA (US) (2022 - 2024)
Company Filing History:
Years Active: 2021-2026
Title: The Innovative Journey of Inventor Tahamtan Ahmadi
Introduction
Tahamtan Ahmadi, a dedicated inventor based in Rydal, PA, has made significant contributions to the field of biotechnology. With a total of seven patents to his name, he has focused primarily on developing bispecific antibodies aimed at treating various forms of leukemia.
Latest Patents
Ahmadi's latest patents include groundbreaking work on bispecific antibodies against CD3 and CD20, specifically designed for treating chronic lymphocytic leukemia (CLL). These patents outline methods for clinical treatment that utilize a bispecific antibody to target these markers in human subjects suffering from CLL. Additionally, he has developed a bispecific antibody for use in combination therapy targeting diffuse large B-cell lymphoma (DLBCL). This innovation also details methods for treating high-risk DLBCL patients using the bispecific antibody alongside the standard R-CHOP regimen, which consists of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone.
Career Highlights
Throughout his career, Ahmadi has worked with prominent organizations such as Genmab A/S and Janssen Biotech, Inc., where he has collaborated on various research projects aimed at advancing cancer treatment. His experience in these reputable companies has allowed him to refine his skills and contribute to significant advancements in therapeutic approaches.
Collaborations
In his journey as an inventor, Ahmadi has had the opportunity to work alongside notable colleagues such as Brian Elliott and Christopher W. L. Chiu. Their collaborative efforts have undoubtedly enriched his research and innovation capabilities in the field of biotech.
Conclusion
Tahamtan Ahmadi's commitment to developing innovative treatments for leukemia demonstrates his valuable contributions to medical science. With a focus on bispecific antibodies, his work represents important strides in the pursuit of effective cancer therapies, underscoring the importance of collaboration and innovation in the field of biotechnology.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile